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Background: An inverse association between serum alanine
aminotransferase (ALT) levels and the risk of myocardial
infarction (MI) has been reported in the general population. We
investigated associations between ALT levels and the risk of
various cardiovascular and cerebrovascular outcomes in a large
cohort study of HIV-positive individuals.
Methods: Using Poisson regression, we investigated associations
between the latest ALT level and MI, coronary heart disease (CHD),
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and stroke, after adjusting for known confounders and cumulative/
recent exposure to antiretroviral drugs. Analyses were also per-
formed for the end points of all-cause/liver-related mortality and
new-onset diabetes mellitus.
Results: By February 2011, participants had experienced 541 MIs,
804 CHD, and 258 stroke events. The MI rate decreased from
3.1/1000 person-years among those with ALT #18 U/L to 2.1/1000
person-years among those with ALT .60 U/L. After adjustment for
confounders, each 2-fold increment in ALT was associated with
a 19% drop in the MI rate {relative rate, 0.81 [95% conﬁdence
interval (CI): 0.74 to 0.89], P = 0.0001}. A weaker inverse associ-
ation was seen for CHD with no indication of a linear association
between ALT levels and stroke (P = 0.72). Adjusted relative rates
were 0.88 (95% CI: 0.81 to 0.97) and 0.70 (95% CI: 0.54 to 0.92) in
those who were hepatitis C virus negative and hepatitis C virus
positive, respectively, and 0.72 (95% CI: 0.58 to 0.89) and 0.84
(0.77 to 0.93) in injection drug users and non-injection drug users,
respectively. Liver-related mortality and diabetes both demonstrated
a positive association with ALT levels, whereas all-cause mortality
showed a U-shaped relationship.
Conclusions: Higher ALT levels are associated with lower MI risk
in HIV-positive individuals, but with higher risks of liver-related
mortality and diabetes mellitus.
Key Words: myocardial infarction, alanine aminotransferase, car-
diovascular disease, coronary heart disease, stroke
(J Acquir Immune Deﬁc Syndr 2013;63:456–463)
INTRODUCTION
High serum alanine aminotransferase (ALT) levels have
been reported to be associated with an increased risk of several
outcomes in both the general and HIV-positive populations,
including diabetes, nonalcoholic fatty liver disease, and both
liver-related and all-cause mortality.1–5 In contrast, Ford et al6
recently reported the unexpected ﬁnding that among individu-
als recruited to 3 general population cohorts [the West of Scot-
land Coronary Prevention Study (WOSCOPS), the Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER), and the
Leiden 85-plus Study], there were inverse associations between
baseline ALT levels within the normal range and all-cause
mortality (over a period of follow-up that ranged from around
4 to 16 years in the 3 cohorts) and mortality from coronary
heart disease (CHD), cancer, and other non-cardiovascular
causes. These associations remained after adjustment for mea-
sured confounders. Individuals included in the studies were
aged from 45 to 85 years, and the predictive ability of ALT
levels was found across the normal range of values. The
authors could not demonstrate a mechanism for their ﬁndings,
but speculated that the inverse associations might reﬂect
impaired synthetic capacity in the liver, reduced liver cell turn-
over, or low skeletal muscle mass, all of which might, them-
selves, be associated with increased mortality.
HIV-positive individuals are at a high risk of elevated
transaminase levels as a result of coinfection with hepatitis B or
C, lifestyle factors (alcohol and drug use), and treatment with
some antiretroviral drugs.7–10 Furthermore, there is increasing
evidence that HIV also plays a role in the development of car-
diovascular disease (CVD), possibly through inﬂammatory
processes, and some antiretroviral drugs also raise CVD
risk.11–13 We investigated associations between ALT levels
and the risk of various cardiovascular and cerebrovascular out-
comes, primarily focusing on myocardial infarction (MI), in
the Data Collection on Adverse Events of Anti-HIV Drugs
(D:A:D) Study.
METHODS
The design of the D:A:D Study has been described
in detail elsewhere.13,14 In brief, it is an observational study
of .49,000 HIV-positive people under care for HIV from 11
cohorts from Europe, Australia, and the United States. All
participants were under active follow-up in their cohorts at
the time of enrollment in the study. The primary study aim
was to investigate the associations between use of antiretro-
viral drugs and risk of CVD and other major clinical events.
Data are collected prospectively during routine clinic visits;
the standardized dataset includes information on sociodemo-
graphic factors, AIDS events and deaths, known risk factors
for CVD, laboratory markers for monitoring HIV (including
CD4 count and HIV RNA) and CVD, antiretroviral treatment,
and treatments that inﬂuence CVD risk. Information on all
incident cases of CVD is reported to the study coordinating
center for validation and coding that is performed blind to the
patient’s antiretroviral treatment status. Information on cause
of death was captured using the Coding of Causes of Death in
HIV (CoDe) form.15,16 The present analyses were limited to
the participating cohorts that provided data on ALT levels.
Statistical Methods
Follow-up time for the analysis was considered from the
date of recruitment to the D:A:D Study until the earliest of
a new event, death, February 1, 2011, or 6 months after the
individual’s last clinic visit. For our primary analyses, we con-
sidered the following events: (1) MI; (2) CHD: MI, sudden
cardiac death, or invasive procedure (coronary artery bypass
graft, carotid endarterectomy, or angioplasty); or (3) Conﬁrmed
stroke. Each individual’s follow-up was split into a series of
consecutive 1-month periods and his/her clinical, immunologic,
and virological status at the start of each period was established
(using the most recently available information before the start
of each period). Each individual’s latest ALT level was cate-
gorized (Table 1), and event rates were calculated for each
stratum. Analyses were performed using Poisson regression
with adjustment for potential confounders (for nonstroke end
points: gender, age, race, mode of HIV acquisition, previous
and family history of CVD, body mass index, smoking status,
clinical cohort, calendar year, cumulative exposure to each
speciﬁc antiretroviral drug, and recent exposure to drugs in
the nucleoside reverse transcriptase inhibitor class; for the
stroke end point: gender, age, previous history of CVD, body
mass index, smoking status, hypertension, and calendar year).
Analyses were also performed with the latest ALT level
included as a continuous covariate (after log2 transformation).
To further assess whether our results were driven by individuals
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who were coinfected with hepatitis C virus (HCV) or who had
a reported history of injection drug use, our analyses were
repeated after stratifying by these factors.
Several sensitivity analyses were also performed for the
MI end point. (1) To investigate possible mechanisms for any
associations seen, we performed analyses that additionally
adjusted for the latest levels of total cholesterol and tri-
glyceride. (2) As statin use has been reported to lead to an
increased risk of diabetes and elevated ALT levels,17 analyses
also included adjustment for exposure to lipid-lowering
drugs. (3) As patients with elevated ALT may die from com-
peting causes (eg, liver failure), we performed an analysis
after excluding all patients from the dataset who died of
non-CVD causes without having an MI. (4) As ALT levels
are highly variable measurements,7 analyses were repeated
after smoothing the longitudinal ALT levels using a running
median of the 3 preceding values. (5) Analyses were repeated
after excluding periods of follow-up when an individual’s
ALT level had not been measured within the past 6 months.
Results of all sensitivity analyses were consistent with our
main analyses and are described only in brief.
Although the cardiovascular and cerebrovascular events
were of primary interest, analyses were also performed
considering all-cause mortality, liver-related mortality, and
new-onset diabetes mellitus as secondary end points. These
secondary end points were chosen as positive controls as the
published literature would suggest that higher ALT levels
should be associated with higher risk of liver-related mortality
and diabetes mellitus; predicted associations with all-cause
mortality are unclear given the many different causes of death
in the cohort.
RESULTS
The study population (from 8 of the 11 participating
cohorts) included 31,235 participants. Three-quarters (73.0%)
of participants were male; ethnic group was white in 53.2%,
black in 7.0%, other in 1.4%, and unknown/not recorded in
38.4% (Table 1). At entry to the study, the median [interquar-
tile range (IQR)] age of patients was 37 (32–44) years and
66.6% had been exposed to antiretroviral therapy. The median
(IQR) CD4 count of participants was 405 (249–591) cells/mm3,
and HIV RNA was 3.0 (1.7–4.5) log10 copies per milliliter.
By February 1, 2011, the participants had experi-
enced 541 MIs over 200,815 person-years follow-up {PYFU;
2.7/1000 PYFU [95% conﬁdence interval (CI): 2.5 to 2.9]},
804 CHD events over 199,972 PYFU [4.0/1000 (95% CI: 3.7
to 4.3) PYFU] and 258 stroke events over 201,925 PYFU
[1.3/1000 (95% CI: 1.1 to 1.4) PYFU]. Patients contributed
a median (IQR) of 10 (4–18) ALT measurements to the anal-
ysis; ALT levels were measured a median (IQR) of 144
(94–186) days apart. Overall, the median ALT level was 28
(IQR: 19–46) U/L with no evidence of a change in level over
time [median (IQR): 28 (18–52) U/L for measurements taken in
2000, 28 (20–43) U/L for measurements taken in 2010/2011].
As expected, ALT values were higher in men, those who were
older, injection drug users, those of white or unknown race,
those with an existing diagnosis of diabetes, and those coin-
fected with hepatitis B virus or HCV, whereas levels were
lower in those of black African race and in those with
a BMI ,18 kg/m2 (data not shown).
The MI event rate decreased from 3.1/1000 PYFU
among those with a latest ALT level #18 U/L to 2.1/1000
PYFU among those with a latest ALT level .60 U/L
(Table 2). After adjustment for known CVD risk factors,
calendar year, and cumulative/recent exposure to each anti-
retroviral drug, there was a clear reduction in MI risk as the
ALT level increased, each 2-fold (log2) increment in ALT
being associated with a 19% drop in the MI rate [0.81
(95% CI: 0.74 to 0.89), P = 0.0001]. Exclusion of individuals
with an ALT level above the upper limit of normal (taken to
be 40 IU for the purposes of this analysis) resulted in a similar
estimate [0.80 (95% CI: 0.68 to 0.95)]. In contrast, although
an inverse association was seen with the CHD end point [0.92
(95% CI: 0.86 to 0.99), P = 0.02], this appeared to be much
weaker than that for MI (an 8% reduction in the risk of CHD
for each 2-fold increment in ALT level), and there was no
clear indication of a linear association between ALT levels
and the risk of stroke (P = 0.72). Thus, the negative associ-
ation appeared to be speciﬁc to MI and did not extend to other
cardio/cerebrovascular end points evaluated.
The estimated adjusted association between MI and the
latest ALT level did not change after further adjustment for
the latest triglyceride/total cholesterol levels [0.81 (95% CI:
0.74 to 0.88), P = 0.0001], or for the use of lipid-lowering
drugs [0.81 (95% CI: 0.74 to 0.88), P = 0.0001]. After
excluding from analysis those patients who died from non–
CVD-related causes, the association between the latest ALT
level and MI risk was again unchanged [0.82 (95% CI: 0.75
to 0.89), P = 0.0001]. Analyses were repeated after smoothing
the longitudinal ALT levels before log2 transformation using
a running median, again with consistent results [0.79 (95%
CI: 0.72 to 0.87), P = 0.0001]. The adjusted relative rate was
0.88 (0.81 to 0.97) in those who were HCV negative and 0.70
(95% CI: 0.54 to 0.92) in those who were HCV positive
TABLE 1. Characteristics of 31,235 Individuals at Entry to the
Study
n (%)
Gender, n (%)
Male 22,788 (73.0)
Female 8447 (27.0)
Mode of HIV acquisition, n (%)
Sex between men 12,950 (41.5)
Injection drug use 5307 (17.0)
Sex between men and women 10,763 (34.5)
Other/unknown 2215 (7.1)
Ethnicity, n (%)
White 16,630 (53.2)
Black African 2188 (7.0)
Other 436 (1.4)
Unknown 11,981 (38.4)
Age (yrs), median (IQR) 37 (32–44)
Prior antiretroviral therapy, n (%) 20,816 (66.6)
HIV RNA #50 copies per mL, n (%) 8502 (29.0)
CD4 count (cells/mm3), median (IQR) 405 (249–591)
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(P value for interaction = 0.15); the adjusted relative rates
were 0.72 (95% CI: 0.58 to 0.89) in injection drug users
and 0.84 (95% CI: 0.77 to 0.93) in non-injection drug users
(P value for interaction = 0.14). Finally, after excluding peri-
ods of follow-up when an individual’s ALT level had not
been measured in the past 6 months, the results were similar
[95% CI: 0.77 (0.69 to 0.87), P = 0.0001].
Analyses of non-cardio/cerebrovascular end points
(Table 3) supported our predeﬁned hypothesized associa-
tions. Both liver-related mortality and diabetes demonstrated
a positive association with ALT levels (ie, higher levels were
associated with increased risk of each event), whereas all-
cause mortality showed a U-shaped relationship with higher
mortality levels in those with either very low (,18 U/L) or
very high (.60 U/L) ALT levels, presumably reﬂecting dif-
ferent associations with ALT and speciﬁc causes of mortality
in the cohort.
DISCUSSION
Using the data from a large prospective study of HIV-
positive individuals, we have conﬁrmed the unexpected
ﬁndings from Ford et al6 of an inverse association between
an individual’s ALT level and his/her risk of MI. In particular,
we found that there was a linear relationship with the latest
ALT level, with the risk of MI progressively decreasing as the
ALT level increased. Our ﬁndings were robust to variations in
the measurement of ALT and could not be explained by
a higher rate of mortality from competing causes in those
with higher ALT levels.
In contrast to Ford’s analysis, where inverse associa-
tions were also seen with all-cause mortality, cancer deaths
(not evaluated as part of the present analysis), and other car-
dio/cerebrovascular end points, our association with ALT did
appear to be speciﬁc to the MI end point. However, it should
be noted that whereas the cohorts included in Ford’s study
included individuals whose ALT levels were largely in the
normal range, HIV-positive individuals in the D:A:D Study
generally have higher ALT levels (eg, around 20% of follow-
up time was spent with an ALT level of .60 U/L); thus, it is
likely that the strong positive associations between ALT and
liver-related mortality and diabetes are driven by individuals
with ALT levels at the higher end of the normal range or
above. Of note, our ﬁndings relating to MI risk, and those
of Ford, are inconsistent with those of Schindhelm et al18 who
noted a higher rate of fatal and nonfatal CHD events in those
with higher ALT levels.
Consistent with other published data, a higher ALT
level was associated with an increased risk of diabetes
mellitus.4 Not surprisingly, we found an increased risk of
liver-related mortality in those with very high ALT levels in
TABLE 2. MI, CHD, and Stroke Event Rates Stratified by Latest (Time-Updated) ALT Level, Unadjusted, and Adjusted* Associations
Between the Latest ALT Level and Each Outcome
Latest ALT
Level (U/L) Events PYFU
Rate (per 1000 PYFU)
(95% CI)
Relative Rate (95% CI)
Unadjusted P Adjusted* P
MI
#18 119 38,354 3.1 (2.6 to 3.7) 1 — 1 —
.18 to #25 98 34,584 2.8 (2.3 to 3.4) 0.91 (0.70 to 1.19) 0.51 0.80 (0.61 to 1.05) 0.10
.25 to #35 99 34,436 2.9 (2.3 to 3.4) 0.93 (0.71 to 1.21) 0.58 0.78 (0.60 to 1.03) 0.08
.35 to #60 83 35,502 2.3 (1.8 to 2.8) 0.75 (0.57 to 1.00) 0.05 0.60 (0.45 to 0.80) 0.0005
.60 72 34,050 2.1 (1.6 to 2.6) 0.68 (0.51 to 0.91) 0.01 0.50 (0.37 to 0.68) 0.0001
Not known 70 23,889 2.9 (2.2 to 3.6) 0.94 (0.70 to 1.27) 0.70 0.65 (0.45 to 0.93) 0.02
/log2 increment 0.89 (0.82 to 0.96) 0.004 0.81 (0.74 to 0.89) 0.0001
CHD
#18 166 38,230 4.3 (3.7 to 5.0) 1 — 1 —
.18 to #25 144 34,445 4.2 (3.5 to 4.9) 0.96 (0.77 to 1.20) 0.74 0.87 (0.70 to 1.09) 0.24
.25 to #35 153 34,246 4.5 (3.8 to 5.2) 1.03 (0.83 to 1.28) 0.80 0.92 (0.73 to 1.15) 0.45
.35 to #60 124 35,313 3.5 (2.9 to 4.1) 0.81 (0.64 to 1.02) 0.07 0.72 (0.57 to 0.91) 0.005
.60 122 33,918 3.6 (3.0 to 4.2) 0.83 (0.66 to 1.05) 0.11 0.76 (0.60 to 0.97) 0.03
Not known 95 23,820 4.0 (3.2 to 4.8) 0.92 (0.71 to 1.18) 0.51 0.73 (0.57 to 0.94) 0.02
/log2 increment 0.94 (0.88 to 1.00) 0.07 0.92 (0.86 to 0.99) 0.02
Conﬁrmed stroke
#18 65 38,484 1.7 (1.3 to 2.1) 1 — 1 —
.18 to #25 42 34,770 1.2 (0.8 to 1.6) 0.72 (0.49 to 1.05) 0.09 0.67 (0.45 to 0.99) 0.05
.25 to #35 37 34,697 1.1 (0.7 to 1.4) 0.63 (0.42 to 0.95) 0.03 0.58 (0.39 to 0.88) 0.01
.35 to #60 31 35,749 0.9 (0.6 to 1.2) 0.51 (0.33 to 0.79) 0.002 0.48 (0.31 to 0.74) 0.001
.60 56 34,222 1.6 (1.2 to 2.1) 0.97 (0.68 to 1.38) 0.86 0.97 (0.67 to 1.40) 0.88
Not known 27 24,003 1.1 (0.7 to 1.6) 0.67 (0.43 to 1.04) 0.08 0.64 (0.41 to 1.01) 0.06
/log2 increment 0.98 (0.87 to 1.09) 0.004 0.98 (0.87 to 1.10) 0.72
*Analyses of MI adjusted for demographic and CVD risk factors and cumulative exposure to speciﬁc antiretroviral drugs, and recent exposure to drugs from the nucleoside reverse
transcriptase inhibitor class; analyses of stroke adjusted for gender, age, previous history of CVD, body mass index, smoking status, hypertension, and calendar year.
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the cohort. The strong association between a higher ALT
level and an increased risk of liver-related mortality has been
reported by others.3 Interestingly, we found a U-shaped asso-
ciation between ALT levels and all-cause mortality, with
a higher mortality risk in those with very low and those with
very high ALT levels. It is likely that the shape of any asso-
ciation with all-cause mortality will depend on the underlying
causes of mortality in the cohort. Trends in causes of death in
the D:A:D Study have recently been presented16; liver-related
mortality currently accounts for 13% of deaths that have
occurred, with deaths from MI accounting for 6%.
We investigated whether the association between low
ALT and a higher MI rate was driven by a higher rate of viral
hepatitis (or injection drug use) in those with high ALT
levels. Around 20% of follow-up time in the D:A:D Study is
contributed by patients who are coinfected with HCV and 6%
by those coinfected with hepatitis B virus19; 17.0% of patients
in the present dataset were infected with HIV via injection
drug use. Although we found a signiﬁcant inverse association
between MI risk and ALT levels regardless of HCV status or
injection drug use, the associations did appear to be numeri-
cally greater in those who were HCV positive and in those
who were infected with HIV through injection drug use (note
that these groups largely overlap). The differences between
these subgroups were not signiﬁcant, however, suggesting
that any differences may simply reﬂect chance variation. Fur-
thermore, the fact that Ford’s study was conducted within the
general population, where only a small proportion of individ-
uals would be expected to have viral infections or to be injec-
tion drug users, suggests that the association is unlikely to be
driven by these factors.
Exposure to some antiretroviral drugs, particularly
nevirapine and ritonavir, is associated with hepatotoxicities
and raised ALT levels; the nucleoside reverse transcriptase
inhibitors, stavudine and didanosine (and possibly zidovu-
dine), may also cause hepatic steatosis that would tend to lead
to elevated ALT levels.7–10,20 It is unlikely that a greater expo-
sure to these drugs could explain the lower risk of MI in those
with high ALT levels for 2 reasons. First, if this were to
explain our ﬁndings, the drugs that are most likely to cause
ALT elevations would also have to be associated with
a reduced MI risk; the only antiretroviral drug where this
might plausibly be the case is nevirapine, which is associated
with a more favorable lipid proﬁle.21 Secondly, our associa-
tions were similar both before and after adjustment for cumu-
lative exposure to speciﬁc antiretroviral drugs and to current
exposure to drugs from the nucleoside reverse transcriptase
inhibitor class. Thus, we do not believe that this is an expla-
nation for our ﬁndings.
Results from a recent meta-analysis of 72 randomized
trials of statins found that statin treatments signiﬁcantly
increased the rate of elevated ALT levels.17 As statin treatment
would reduce the risk of MI in those receiving them, this might
induce an inverse relationship between ALT levels and MI
risk. However, the inverse association was not removed after
adjustment for either the lipid levels themselves or for the use
of lipid-lowering drugs as a class (note that the data collection
for the D:A:D Study does not allow us to differentiate between
statins and other lipid-lowering drugs). Thus, we do not believe
that this is a likely explanation for our ﬁndings.
Finally, it should be noted that our multivariable
regression model included adjustment for current smoking
status. Hence, although cigarette smoking is a known risk
factor for MI and may also lead to a reduction in ALT levels,
it cannot explain the associations seen. Although we do not
capture more detailed information on pack-years or number of
cigarettes smoked, we would not expect this to confound any
associations with ALT and so do not believe that this
additional information would change our conclusions.
Several limitations of our study must be noted. Firstly,
we do not collect information on alcohol use among
participants. It has been suggested that a moderate intake of
alcohol may be beneﬁcial to the coronary arteries,22 and alco-
hol is known to increase ALT levels,23 thus possibly explain-
ing the observed inverse association between increasing ALT
levels and MI risk. However, it should be noted that the
ﬁndings by Ford et al6 were adjusted for alcohol consump-
tion, and so this did not appear to explain the inverse associ-
ation in their study. Furthermore, we did not ﬁnd a similarly
strong inverse association with the CHD end point, although
alcohol may also be expected to lead to a reduced risk of this
broader end point. As ALT levels were not routinely
TABLE 3. Adjusted* Associations Between Latest ALT Level
and Event Rates for (1) All-Cause Mortality, (2) Liver-Related
Mortality, and (3) Diabetes
Latest ALT Level (U/L) Relative Rate (95% CI) P
All-cause mortality [2230 events, 202,727 PYFU, rate (95% CI)/1000 PYFU:
11.0 (10.5 to 11.5)]
#18 1 —
.18 to #25 0.74 (0.64 to 0.86) 0.0001
.25 to #35 0.87 (0.75 to 1.00) 0.05
.35 to #60 0.99 (0.87 to 1.14) 0.91
.60 1.38 (1.21 to 1.57) 0.0001
Not known 0.18 (0.13 to 0.24) 0.0001
/log2 increment 1.14 (1.10 to 1.18) 0.0001
Liver-related mortality [329 events, 202,727 PYFU, rate (95% CI)/1000
PYFU: 1.62 (1.45 to 1.80)]
#18 1 —
.18 to #25 0.96 (0.49 to 1.89) 0.91
.25 to #35 2.01 (1.13 to 3.56) 0.02
.35 to #60 4.08 (2.44 to 6.85) 0.0001
.60 6.88 (4.15 to 11.40) 0.0001
Not known 0.59 (0.24 to 1.48) 0.26
/log2 increment 1.58 (1.45 to 1.72) 0.0001
Diabetes [922 events, 198,079 PYFU, rate (95% CI)/1000 PYFU: 4.78 (4.47
to 5.08)]
#18 1 —
.18 to #25 1.05 (0.80 to 1.39) 0.72
.25 to #35 1.50 (1.16 to 1.94) 0.002
.35 to #60 2.15 (1.68 to 2.73) 0.0001
.60 2.86 (2.24 to 3.65) 0.0001
Not known 2.08 (1.51 to 2.87) 0.0001
/log2 increment 1.33 (1.26 to 1.41) 0.0001
*Adjusted for demographic and CVD risk factors and cumulative exposure to
speciﬁc antiretroviral drugs, and recent exposure to drugs from the nucleoside reverse
transcriptase inhibitor class.
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measured systematically in individuals with HIV until rela-
tively recently and not all cohorts routinely captured these
measurements, our analyses could only include patients from
8 of the 11 participating cohorts. However, although this
reduces the amount of follow-up that can be used in analysis,
it does result in a more contemporaneous population increas-
ing the clinical relevance of the ﬁndings to current treat-
ment protocols. Given the characteristics of the patients in
the D:A:D Study, our results are generalizable to a largely
male population. As an observational study, our analyses are
always subject to the possibility of unmeasured confounding
and other potential sources of bias, limiting any statements
regarding a causal association between lower ALT levels and
MI risk. Finally, although the normal ALT range differs
between men and women, the small number of women in
the study and their lower MI risk limits our ability to perform
stratiﬁed analyses by gender.
In summary, we conﬁrm that higher ALT levels are
associated with a lower MI risk in the D:A:D Study, but with
higher risks of liver-related mortality and diabetes mellitus.
As yet, there is no identiﬁed biological mechanism to explain
the association between a low ALT level and a higher MI
risk; although it is interesting to speculate that such individ-
uals might be younger or healthier, we see no reason why this
group should have an increased risk of MI. Furthermore, we
are unaware of any clinical conditions or factors that would
lead to lower than normal ALT levels that might lead to the
higher MI risk. Thus, it is hard to comment on the clinical
implications of these ﬁndings at this stage. Rather, in
replicating the ﬁndings of Ford et al6 in a different setting,
we hope to encourage other research groups to investigate
possible biological mechanisms.
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APPENDIX 1
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Smith, A. Phillips*, A. Mocroft, J. Tverland, J. Nielsen, J. D. Lundgren (chair).
D:A:D Data Managers: R. Salbøl Brandt (coordinator), M. Ricken-
bach, I. Fanti, E. Krum, M. Hillebregt, S. Geffard, A. Sundström, M. Del-
forge, E. Fontas, F. Torres, H. McManus, S. Wright, J. Kjær.
Endpoint Veriﬁcation Group: A. Sjøl (CVD primary endpoint), P.
Meidahl (oncology), J. Helweg-Larsen (hematology), J. Schmidt Iversen
(nephrology).
The members of the 11 Cohorts are as follows:
ATHENA (AIDS Therapy Evaluation Project Netherlands):
Central coordination: F. de Wolf, S. Zaheri, M Hillebregt L. Gras.
Participating physicians (¤ indicates Site coordinating physicians): Aca-
demisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam:
J. M. Prins¤, T. W. Kuijpers, H. J. Scherpbier, K. Boer, J. T. M. van der Meer,
F. W. M. N. Wit, M. H. Godfried, P. Reiss*, T. van der Poll, F. J. B. Nellen,
J Acquir Immune Defic Syndr  Volume 63, Number 4, August 1, 2013 ALT and Cardio/Cerebrovascular Events
 2013 Lippincott Williams & Wilkins www.jaids.com | 461
J. M. A. Lange, S. E. Geerlings, M. van Vugt, S. M. E. Vrouenraets, D. Pajkrt,
M. van der Valk. Academisch Ziekenhuis Maastricht, Maastricht: G. Schreij¤,
S. Lowe, A. Oude Lashof. Catharina-ziekenhuis, Eindhoven: M. J. H. Pronk¤,
B. Bravenboer. Erasmus Medisch Centrum, Rotterdam: M. E. van der Ende¤,
T. E. M. S. de Vries-Sluijs, C. A. M. Schurink, M. van der Feltz, J. L. Nouwen,
L. B. S. Gelinck, A. Verbon, B. J. A. Rijnders, L. Slobbe. Erasmus Medisch
Centrum–Sophia, Rotterdam: N. G. Hartwig, G. J. A. Driessen. Flevozieken-
huis, Almere: J. Branger¤. HagaZiekenhuis, Den Haag: R. H. Kauffmann¤, E.
F. Schippers. Isala Klinieken, Zwolle: P. H. P. Groeneveld¤, M. A. Alleman,
J. W. Bouwhuis. Kennemer Gasthuis: R. W. ten Kate¤, R. Soetekouw. Leids
Universitair Medisch Centrum, Leiden: F. P. Kroon¤, P. J. van den Broek, J. T.
van Dissel, S. M. Arend, C. van Nieuwkoop, M. G. J. de Boer, H. Jolink.
Maasstadziekenhuis, Rotterdam: J. G. den Hollander¤, K. Pogany. Medisch
Centrum Alkmaar, Alkmaar: G. van Twillert¤, W. Kortmann. Medisch Cen-
trum Haaglanden, Den Haag: R. Vriesendorp¤, E. M. S. Leyten. Medisch
Spectrum Twente, Enschede: C. H. H. ten Napel¤, G. J. Kootstra. Onze Lieve
Vrouwe Gasthuis, Amsterdam: K. Brinkman¤, W. L. Blok, P. H. J. Frissen,
W. E. M. Schouten, G. E. L. van den Berk. Sint Elisabeth Ziekenhuis, Tilburg:
J. R. Juttmann¤, M. E. E. van Kasteren, A. E. Brouwer. Sint Lucas Andreas
Ziekenhuis, Amsterdam: J. Veenstra¤, K. D. Lettinga. Slotervaartziekenhuis,
Amsterdam: J. W. Mulder¤, E. C. M. van Gorp, P. M. Smit, S. Weijer. Stichting
Medisch Centrum Jan van Goyen, Amsterdam: A. van Eeden, D. W. M. Ver-
hagen¤. Universitair Medisch Centrum Groningen, Groningen: H. G. Sprenger
¤, R. Doedens, E. H. Scholvinck, S. van Assen, C. J. Stek. Universitair Medisch
Centrum Sint Radboud, Nijmegen: P. P. Koopmans¤, R. de Groot, M. Keuter,
A. J. A. M. van der Ven, H. J. M. ter Hofstede, M. van der Flier, A. M.
Brouwer, A. S. M. Dofferhoff. Universitair Medisch Centrum Utrecht, Utrecht:
A. I. M. Hoepelman¤, T. Mudrikova, M. M. E. Schneider, C. A. J. J. Jaspers, P.
M. Ellerbroek, E. J. G. Peters, L. J. Maarschalk-Ellerbroek, J. J. Oosterheert, J.
E. Arends, M. W. M. Wassenberg, J. C. H. van der Hilst. Vrije Universiteit
Amsterdam, Amsterdam: S. A. Danner¤, M. A. van Agtmael, J. de Vocht, R.
M. Perenboom, F. A. P. Claessen, W. F. W. Bierman, E. V. de Jong, E. A. bij
de Vaate. Wilhelmina Kinderziekenhuis, Utrecht: S. P. M. Geelen, T. F. W.
Wolfs. Ziekenhuis Rijnstate, Arnhem: C. Richter¤, J. P. van der Berg, E. H.
Gisolf. Ziekenhuis Walcheren, Vlissingen: M. van den Berge¤, A. Stegeman.
Medisch Centrum Leeuwarden, Leeuwarden: D. P. F. van Houte¤, M. B. Polée,
M. G. A. van Vonderen. Sint Elisabeth Hospitaal, Willemstad - Curaçao: C.
Winkel, A. J. Duits.
ANRS CO3 Aquitaine Cohort (France)
Composition of the Groupe d’Epidémiologie Clinique du Sida en
Aquitaine (GECSA):
Coordination: F. Dabis*. Scientiﬁc committee: F. Bonnet, F. Dabis,
M. Dupon, G. Chêne, H. Fleury, D. Lacoste, D. Malvy, P. Mercié, I. Pelle-
grin, P. Morlat, D. Neau, JL. Pellegrin, R. Thiébaut, K. Titier. Epidemiology
and Methodology: M. Bruyand, G. Chêne, F. Dabis, S. Lawson-Ayayi,
R. Thiébaut, L. Wittkop. Infectious Diseases and Internal Medicine: F. Bon-
nal, F. Bonnet, N. Bernard, L. Caunègre, C. Cazanave, J. Ceccaldi, D. Cham-
bon, I. Chossat, K. Courtaud, FA. Dauchy, S. De Witte, M. Dupon,
A. Dupont, P. Duffau, H. Dutronc, S. Farbos, V. Gaboriau, MC. Gemain,
Y. Gerard, C. Greib, M. Hessamfar, D. Lacoste, P. Lataste, S. Lafarie-Castet,
E. Lazaro, M. Longy-Boursier, D. Malvy, JP. Meraud, P. Mercié, E. Monlun,
P. Morlat, D. Neau, A. Ochoa, JL. Pellegrin, T. Pistone, JM. Ragnaud, MC.
Receveur, J. Roger-Schmeltz, S. Tchamgoué, P. Thibaut, MA. Vandenhende,
JF. Viallard. Immunology: JF. Moreau, I. Pellegrin. Virology: H. Fleury, ME.
Lafon, B. Masquelier, P. Trimoulet. Pharmacology: D. Breilh, K. Titier. Drug
monitoring: F. Haramburu, G. Miremont-Salamé. Data collection and pro-
cessing: MJ. Blaizeau, M. Decoin, J. Delaune, S. Delveaux, C. D’Ivernois,
C. Hanappier, O. Leleux, B. Uwamaliya-Nziyumvira, X. Sicard. Computing
and Statistical analysis: S. Geffard, J. Leray, G. Palmer, D. Touchard.
AHOD (Australian HIV Observational Database, Australia):
Central coordination: M. Law *, K. Petoumenos, H. McManus,
S. Wright, C. Bendall (Sydney, New South Wales).
Participating physicians (city, state): R. Moore, S. Edwards, J. Hoy,
K. Watson, N. Roth, J. Nicholson (Melbourne, Victoria); M Bloch, T. Franic,
D. Baker, R. Vale, A. Carr, D. Cooper (Sydney, New South Wales); J. Chuah,
M. Ngieng (Gold Coast, Queensland), D. Nolan, J. Skett (Perth, Western
Australia).
BASS (Spain):
Central coordination: G. Calvo, F. Torres, S. Mateu (Barcelona).
Participating physicians (city): P. Domingo, M. A. Sambeat, J. Gatell,
E. Del Cacho, J. Cadafalch, M. Fuster (Barcelona); C. Codina, G. Sirera, A.
Vaqué (Badalona).
The Brussels St Pierre Cohort (Belgium): Coordination: S. De Wit*,
N. Clumeck, M. Delforge, C. Necsoi. Participating physicians: N. Clumeck,
S. De Wit, AF Gennotte, M. Gerard, K. Kabeya, D. Konopnicki, A. Libois, C.
Martin, M. C. Payen, P. Semaille, Y. Van Laethem.
CPCRA (USA):
Central coordination: J. Neaton, G. Bartsch, W. M. El-Sadr*, E.
Krum, G. Thompson, D. Wentworth.
Participating physicians (city, state): R. Luskin-Hawk (Chicago, IL);
E. Telzak (Bronx, NY); W. M. El-Sadr (Harlem, NY); D. I. Abrams (San
Francisco, CA); D. Cohn (Denver, CO); N. Markowitz (Detroit, MI); R.
Arduino (Houston, TX); D. Mushatt (New Orleans, LA); G. Friedland (New
Haven, CT); G. Perez (Newark, NJ); E. Tedaldi (Philadelphia, PA); E. Fisher
(Richmond, VA); F. Gordin (Washington, DC); L. R. Crane (Detroit, MI); J.
Sampson (Portland, OR); J. Baxter (Camden, NJ).
EuroSIDA (multinational)
Coordinating Centre: J. Lundgren*, O. Kirk*, A. Mocroft, A. Cozzi-
Lepri, D. Grint, D. Podlekareva, J. Kjær, L. Peters, J. Reekie, J. Kowalska, J.
Tverland, A. H. Fischer, J. Nielsen.
Participating countries and physicians Argentina: (M. Losso), C.
Elias, Hospital JM Ramos Mejia, Buenos Aires.
Austria: (N. Vetter), Pulmologisches Zentrum der Stadt Wien,
Vienna; R. Zangerle, Medical University Innsbruck, Innsbruck.
Belarus: (I. Karpov), A. Vassilenko, Belarus State Medical Univer-
sity, Minsk; V. M. Mitsura, Gomel State Medical University, Gomel; O.
Suetnov, Regional AIDS Centre, Svetlogorsk.
Belgium: (N. Clumeck), S. De Wit, M Delforge, Saint-Pierre Hospital,
Brussels; R. Colebunders, Institute of Tropical Medicine, Antwerp; L.
Vandekerckhove, University Ziekenhuis Gent, Gent.
Bosnia-Herzegovina: (V. Hadziosmanovic), Klinicki Centar Univer-
ziteta Sarajevo, Sarajevo.
Bulgaria: (K. Kostov), Infectious Diseases Hospital, Soﬁa.
Croatia: (J. Begovac), University Hospital of Infectious Diseases,
Zagreb.
Czech Republic: (L. Machala), D. Jilich, Faculty Hospital Bulovka,
Prague; D. Sedlacek, Charles University Hospital, Plzen.
Denmark: (J. Nielsen), G. Kronborg, T. Benﬁeld, M. Larsen,
Hvidovre Hospital, Copenhagen; J. Gerstoft, T. Katzenstein, A-B. E. Hansen,
P. Skinhøj, Rigshospitalet, Copenhagen; C. Pedersen, Odense University
Hospital, Odense; L. Ostergaard, Skejby Hospital, Aarhus.
Estonia: (K. Zilmer), West-Tallinn Central Hospital, Tallinn; J. Smidt,
Nakkusosakond Siseklinik, Kohtla-Järve.
Finland: (M. Ristola), Helsinki University Central Hospital, Helsinki.
France: (C. Katlama), Hôpital de la Pitié-Salpétière, Paris; J-P. Viard,
Hôpital Necker-Enfants Malades, Paris; P-M. Girard, Hospital Saint-Antoine,
Paris; J. M. Livrozet, Hôpital Edouard Herriot, Lyon; P. Vanhems, University
Claude Bernard, Lyon; C. Pradier, Hôpital de l’Archet, Nice; F. Dabis,
D. Neau, Unité INSERM, Bordeaux.
Germany: (J. Rockstroh), Universitäts Klinik Bonn; R. Schmidt, Med-
izinische Hochschule Hannover; J. van Lunzen, O. Degen, University Med-
ical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; H. J.
Stellbrink, IPM Study Center, Hamburg; S. Staszewski, JW Goethe Univer-
sity Hospital, Frankfurt; J. Bogner, Medizinische Poliklinik, Munich; G.
Fätkenheuer, Universität Köln, Cologne.
Greece: (J. Kosmidis), P. Gargalianos, G. Xylomenos, J. Perdios,
Athens General Hospital; G. Panos, A. Filandras, E. Karabatsaki, ﬁrst IKA
Hospital; H. Sambatakou, Ippokration Genereal Hospital, Athens.
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Hungary: (D. Banhegyi), Szent Lásló Hospital, Budapest.
Ireland: (F. Mulcahy), St. James’s Hospital, Dublin.
Israel: (I. Yust), D. Turner, M. Burke, Ichilov Hospital, Tel Aviv; S.
Pollack, G. Hassoun, Rambam Medical Center, Haifa; S. Maayan, Hadassah
University Hospital, Jerusalem.
Italy: (S. Vella), Istituto Superiore di Sanità, Rome; R. Esposito,
I. Mazeu, C. Mussini, Università Modena, Modena; C. Arici, Ospedale
Riuniti, Bergamo; R. Pristera, Ospedale Generale Regionale, Bolzano;
F. Mazzotta, A. Gabbuti, Ospedale S Maria Annunziata, Firenze; V. Vullo,
M. Lichtner, University di Roma la Sapienza, Rome; A. Chirianni, E. Monte-
sarchio, M. Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital,
Napoli; G. Antonucci, A. Testa, P. Narciso, C. Vlassi, M. Zaccarelli, Istituto
Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A. Lazzarin,
A. Castagna, N. Gianotti, Ospedale San Raffaele, Milan; M. Galli, A. Ridolfo,
Osp. L. Sacco, Milan; A. d’Arminio Monforte, Istituto Di Clinica Malattie
Infettive e Tropicale, Milan.
Latvia: (B. Rozentale), I. Zeltina, Infectology Centre of Latvia, Riga.
Lithuania: (S. Chaplinskas), Lithuanian AIDS Centre, Vilnius.
Luxembourg: (R. Hemmer), T. Staub, Centre Hospitalier, Luxembourg.
Netherlands: (P. Reiss*), Academisch Medisch Centrum bij de Uni-
versiteit van Amsterdam, Amsterdam.
Norway: (V. Ormaasen), A. Maeland, J. Bruun, Ullevål Hospital, Oslo.
Poland: (B. Knysz), J. Gasiorowski, Medical University, Wroclaw;
A. Horban, E. Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw;
A. Grzeszczuk, R. Flisiak, Medical University, Bialystok; A. Boron-
Kaczmarska, M. Pynka, M. Parczewski, Medical Univesity, Szczecin;
M. Beniowski, E. Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow;
H. Trocha, Medical University, Gdansk; E. Jablonowska, E. Malolepsza,
K. Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz.
Portugal: (F. Antunes), M. Doroana, L. Caldeira, Hospital Santa
Maria, Lisbon; K. Mansinho, Hospital de Egas Moniz, Lisbon; F. Maltez,
Hospital Curry Cabral, Lisbon.
Romania: (D. Duiculescu), Spitalul de Boli Infectioase si Tropicale:
Dr. Victor Babes, Bucarest.
Russia: (A. Rakhmanova), Medical Academy Botkin Hospital, St
Petersburg; N. Zakharova, St Petersburg AIDS Centre, St Peterburg; S.
Buzunova, Novgorod Centre for AIDS, Novgorod.
Serbia: (D. Jevtovic), The Institute for Infectious and Tropical
Diseases, Belgrade.
Slovakia: (M. Mokráš), D. Staneková, Dérer Hospital, Bratislava.
Slovenia: (J. Tomazic), University Clinical Centre Ljubljana, Ljubljana.
Spain: (J. González-Lahoz), V. Soriano, P. Labarga, J. Medrano,
Hospital Carlos III, Madrid; S. Moreno, J. M. Rodriguez, Hospital Ramon
y Cajal, Madrid; B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig, I. Bravo,
Hospital Germans Trias i Pujol, Badalona; J. M. Gatell, J. M. Miró, Hospital
Clinic i Provincial, Barcelona; P. Domingo, M. Gutierrez, G. Mateo, M. A.
Sambeat, Hospital Sant Pau, Barcelona.
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